|
PHF20 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.64013247427874E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.23023813358714E-12 |
| Normal-vs-Stage2 |
2.65690000000873E-08 |
| Normal-vs-Stage3 |
3.88840071252616E-11 |
| Normal-vs-Stage4 |
1.88430049341548E-10 |
| Stage1-vs-Stage2 |
8.435600E-01 |
| Stage1-vs-Stage3 |
5.743000E-01 |
| Stage1-vs-Stage4 |
2.063600E-01 |
| Stage2-vs-Stage3 |
8.427800E-01 |
| Stage2-vs-Stage4 |
4.054000E-01 |
| Stage3-vs-Stage4 |
4.508200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.33226762955019E-13 |
| Normal-vs-AfricanAmerican |
8.009800E-04 |
| Normal-vs-Asian |
2.24070000331977E-08 |
| Caucasian-vs-AfricanAmerican |
1.660560E-01 |
| Caucasian-vs-Asian |
9.377600E-01 |
| AfricanAmerican-vs-Asian |
2.235600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.53221879628518E-12 |
| Normal-vs-Female |
1.86839432814168E-12 |
| Male-vs-Female |
4.154200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.79109998738647E-10 |
| Normal-vs-Age(41-60Yrs) |
4.2899017671516E-13 |
| Normal-vs-Age(61-80Yrs) |
5.35937960677302E-12 |
| Normal-vs-Age(81-100Yrs) |
3.608200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.239400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.697180E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.829600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.080000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.326400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.351600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.341400E-01 |
| Classical-VS-Follicular |
3.643400E-03 |
| Classical-VS-Other |
7.672500E-02 |
| Classical-VS-Normal |
4.47909487277798E-11 |
| Tall-VS-Follicular |
2.474600E-01 |
| Tall-VS-Other |
1.486780E-01 |
| Tall-VS-Normal |
9.99339999974147E-07 |
| Follicular-VS-Other |
4.381000E-01 |
| Follicular-VS-Normal |
2.40929498573905E-12 |
| Other-VS-Normal |
5.90809999999609E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.99520433297585E-15 |
| Normal-vs-N1 |
5.19839948864842E-10 |
| N0-vs-N1 |
6.284200E-01 |
|
|
